Resistance mechanisms to tyrosine kinase inhibitors in solid tumors

Project Information

TKI resistance

Grant agreement ID: 717034

DOI 10.3030/717034

Project closed

EC signature date 28 November 2016

Start date 1 December 2016

End date 30 November 2021

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 1 500 000,00

EU contribution € 1 500 000,00

Coordinated by

INSTITUT GUSTAVE ROUSSY
France

Publications

Peer reviewed articles (19)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Author(s): Gonzalo Recondo, Linda Mahjoubi, Aline Maillard, Yohann Loriot, Ludovic Bigot, Francesco Facchinetti, Rastislav Bahleda, Anas Gazzah, Antoine Hollebecque, Laura Mezquita, David Planchard, Charles Naltet, Pernelle Lavaud, Ludovic Lacroix, Catherine Richon, Aurelie Abou Lovergne, Thierry De Baere, Lambros Tselikas, Olivier Deas, Claudio Nicotra, Maud Ngo-Camus, Rosa L. Frias, Eric Solary, Eric Angev
Published in: npj Precision Oncology, Issue 4/1, 2020, ISSN 2397-768X
Publisher: Nature Publishing Group
DOI: 10.1038/s41698-020-00130-7

Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Author(s): Marine Valery, Francesco Facchinetti, David Malka, Michel Ducreux, Luc Friboulet, Antoine Hollebecque
Published in: Digestive and Liver Disease, Issue 2021 Sep 20;S1590-8658(21)00770-2, 2021, ISSN 1590-8658
Publisher: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.dld.2021.09.001

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib

Author(s): Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C. Newton, Huiling Zhen, Luis Feliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn
Published in: Cancer Discovery, 2020, Page(s) CD-20-0766, ISSN 2159-8274
Publisher: American Association for Cancer Research Inc.
DOI: 10.1158/2159-8290.cd-20-0766

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

Author(s): Francesco Facchinetti, Ludovic Lacroix, Laura Mezquita, Jean-Yves Scoazec, Yohann Loriot, Lambros Tselikas, Anas Gazzah, Etienne Rouleau, Julien Adam, Stefan Michiels, Christophe Massard, Fabrice André, Ken A. Olaussen, Gilles Vassal, Karen Howarth, Benjamin Besse, Jean-Charles Soria, Luc Friboulet, David Planchard
Published in: European Journal of Cancer, Issue 132, 2020, Page(s) 211-223, ISSN 0959-8049
Publisher: Pergamon Press Ltd.
DOI: 10.1016/j.ejca.2020.03.025

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Author(s): Mihaela Aldea, Lizza Hendriks, Laura Mezquita, Cécile Jovelet, David Planchard, Edouard Auclin, Jordi Remon, Karen Howarth, Jose Carlos Benitez, Anas Gazzah, Pernelle Lavaud, Charles Naltet, Ludovic Lacroix, Frank de Kievit, Clive Morris, Emma Green, Maud Ngo-Camus, Etienne Rouleau, Christophe Massard, Caroline Caramella, Luc Friboulet, Benjamin Besse
Published in: Journal of Thoracic Oncology, Issue 15/3, 2020, Page(s) 383-391, ISSN 1556-0864
Publisher: Lippincott Williams & Wilkins Ltd.
DOI: 10.1016/j.jtho.2019.11.024

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Author(s): Diego Enrico, Ludovic Lacroix, Jeanne Chen, Etienne Rouleau, Jean-Yves Scoazec, Yohann Loriot, Lambros Tselikas, Cécile Jovelet, David Planchard, Anas Gazzah, Laura Mezquita, Maud Ngo-Camus, Stefan Michiels, Christophe Massard, Gonzalo Recondo, Francesco Facchinetti, Jordi Remon, Jean-Charles Soria, Fabrice André, Gilles Vassal, Luc Friboulet, Benjamin Besse
Published in: JTO Clinical and Research Reports, Issue 1/2, 2020, Page(s) 100023, ISSN 2666-3643
Publisher: Elsevier
DOI: 10.1016/j.jtocrr.2020.100023

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Author(s): Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama
Published in: Journal of Experimental Medicine, Issue 216/4, 2019, Page(s) 982-1000, ISSN 0022-1007
Publisher: Rockefeller University Press
DOI: 10.1084/jem.20180870

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

Author(s): Francesco Facchinetti, Giulio Rossi, Emilio Bria, Jean-Charles Soria, Benjamin Besse, Roberta Minari, Luc Friboulet, Marcello Tiseo
Published in: Cancer Treatment Reviews, Issue 55, 2017, Page(s) 83-95, ISSN 0305-7372
Publisher: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.ctrv.2017.02.010

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Author(s): Laura Mezquita, Aurélie Swalduz, Cécile Jovelet, Sandra Ortiz-Cuaran, Karen Howarth, David Planchard, Virginie Avrillon, Gonzalo Recondo, Solène Marteau, Jose Carlos Benitez, Frank De Kievit, Vincent Plagnol, Ludovic Lacroix, Luc Odier, Etienne Rouleau, Pierre Fournel, Caroline Caramella, Claire Tissot, Julien Adam, Samuel Woodhouse, Claudio Nicotra, Edouard Auclin, Jordi Remon, Clive Morris, E
Published in: JCO Precision Oncology, Issue 4, 2020, Page(s) 272-282, ISSN 2473-4284
Publisher: PMC
DOI: 10.1200/po.19.00281

<p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>

Author(s): Francesco Facchinetti, Luc Friboulet
Published in: Lung Cancer: Targets and Therapy, Issue Volume 10, 2019, Page(s) 87-94, ISSN 1179-2728
Publisher: Dove Medical Press Ltd
DOI: 10.2147/lctt.s190786

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer

Author(s): Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Aït Oukhatar
Published in: Clinical Cancer Research, Issue 26/23, 2020, Page(s) 6242-6253, ISSN 1078-0432
Publisher: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-20-1037

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Author(s): Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
Published in: Nature Reviews Clinical Oncology, 2018, ISSN 1759-4774
Publisher: Nature Publishing Group
DOI: 10.1038/s41571-018-0081-4

Facts and new hopes on selective FGFR inhibitors in solid tumors

Author(s): Francesco Facchinetti, Antoine Hollebecque, Rastilav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet
Published in: Clinical Cancer Research, 2019, Page(s) clincanres.2035.2019, ISSN 1078-0432
Publisher: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-2035

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Author(s): Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hol
Published in: Clinical Cancer Research, 2019, Page(s) clincanres.1104.2019, ISSN 1078-0432
Publisher: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-1104

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Author(s): Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Published in: Nature Communications, Issue 12/1, 2021, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-021-21396-w

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer

Author(s): Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Laura Mezquita, Mélanie Laporte, Aurélie Honoré, Yann Lecluse, Pauline Queffelec, Maud NgoCamus, Claudio Nicotra, Jordi Remon, Ludovic Lacroix, David Planchard, Luc Friboulet, Benjamin Besse, Françoise Farace
Published in: Clinical Cancer Research, Issue 25/22, 2019, Page(s) 6671-6682, ISSN 1078-0432
Publisher: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-19-1176

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Author(s): Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman
Published in: Cancer Discovery, Issue 8/6, 2018, Page(s) 714-729, ISSN 2159-8274
Publisher: American Association for Cancer Research Inc.
DOI: 10.1158/2159-8290.cd-17-1256

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

Author(s): Francesco Facchinetti, Luc Friboulet
Published in: Translational Lung Cancer Research, Issue 7/S2, 2018, Page(s) S103-S106, ISSN 2218-6751
Publisher: AME
DOI: 10.21037/tlcr.2018.02.04

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

Author(s): Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L
Published in: Annals of oncology, 2022, ISSN 0923-7534
Publisher: Oxford University Press
DOI: 10.1016/j.annonc.2022.01.004

Thesis and dissertations (1)

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC

Author(s): Recondo, Gonzalo
Published in: "Cancer. Université Paris Saclay (COmUE); Universidad de Buenos Aires, 2019. English. &#x27E8;NNT : 2019SACLS248&#x27E9;", 2019
Publisher: Université Paris Saclay